{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:47:27Z","timestamp":1772851647820,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40262-024-01420-0","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T19:35:34Z","timestamp":1726774534000},"page":"1423-1434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug\u2013Drug Interactions for Firsocostat, a Liver-Targeted Inhibitor of Acetyl-CoA Carboxylase"],"prefix":"10.1007","volume":"63","author":[{"given":"Elijah J.","family":"Weber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islam R.","family":"Younis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8461-4453","authenticated-orcid":false,"given":"Cara","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann R.","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy R.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4937-2775","authenticated-orcid":false,"given":"Ahmed A.","family":"Othman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"1420_CR1","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547\u201354.","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"1420_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/liv.14910","volume":"41","author":"A Armandi","year":"2021","unstructured":"Armandi A, Bugianesi E. Natural history of NASH. Liver Int. 2021;41(Suppl 1):78\u201382.","journal-title":"Liver Int"},{"key":"1420_CR3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/apt.17158","volume":"56","author":"L Henry","year":"2022","unstructured":"Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther. 2022;56:942\u201356.","journal-title":"Aliment Pharmacol Ther"},{"key":"1420_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274\u201385.","journal-title":"Aliment Pharmacol Ther"},{"key":"1420_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","volume":"140","author":"CD Williams","year":"2011","unstructured":"Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124\u201331.","journal-title":"Gastroenterology"},{"key":"1420_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"1420_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","volume":"77","author":"N Alkhouri","year":"2022","unstructured":"Alkhouri N, Herring R, Kabler H, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial. J Hepatol. 2022;77:607\u201318.","journal-title":"J Hepatol"},{"key":"1420_CR8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/hep.29246","volume":"66","author":"K Stiede","year":"2017","unstructured":"Stiede K, Miao W, Blanchette HS, et al. Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: a randomized, double-blind, crossover study. Hepatology. 2017;66:324\u201334.","journal-title":"Hepatology"},{"key":"1420_CR9","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","volume":"155","author":"R Loomba","year":"2018","unstructured":"Loomba R, Kayali Z, Noureddin M, et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology. 2018;155:1463-73.e6.","journal-title":"Gastroenterology"},{"key":"1420_CR10","doi-asserted-by":"publisher","first-page":"S501","DOI":"10.1016\/S0168-8278(16)00866-7","volume":"64","author":"W Westlin","year":"2016","unstructured":"Westlin W, Harriman G, Harwood H, et al. NDI-010976, a potent, liver-directed, oral inhibitor of acetyl Coa carboxylase for non-alcoholic steatohepatitis: a phase 1 single ascending dose study in healthy volunteers. J Hepatol. 2016;64:S501\u20132.","journal-title":"J Hepatol"},{"key":"1420_CR11","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/jcph.2206","volume":"63","author":"E Weber","year":"2023","unstructured":"Weber E, Younis IR, Nelson C, et al. Effect of renal impairment on the pharmacokinetics of firsocostat, an acetyl-coenzyme A carboxylase inhibitor, and cilofexor, a selective nonsteroidal farnesoid X receptor agonist. J Clin Pharmacol. 2023;63:560\u20138.","journal-title":"J Clin Pharmacol"},{"key":"1420_CR12","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1002\/cpt.2252","volume":"111","author":"C-H Hsueh","year":"2022","unstructured":"Hsueh C-H, Qin A, West S, Chung C, Othman A. A phase 1 mass balance study of firsocostat, a liver-targeted acetyl-CoA carboxylase inhibitor. Clin Pharmacol Ther. 2022;111:S24.","journal-title":"Clin Pharmacol Ther"},{"key":"1420_CR13","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/cpt.1435","volume":"105","author":"A Tornio","year":"2019","unstructured":"Tornio A, Filppula AM, Niemi M, Backman JT. Clinical studies on drug\u2013drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation. Clin Pharmacol Ther. 2019;105:1345\u201361.","journal-title":"Clin Pharmacol Ther"},{"key":"1420_CR14","doi-asserted-by":"publisher","first-page":"7023","DOI":"10.3390\/ijms21197023","volume":"21","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li P, Zhang Z, et al. Prediction of cyclosporin-mediated drug interaction using physiologically based pharmacokinetic model characterizing interplay of drug transporters and enzymes. Int J Mol Sci. 2020;21:7023.","journal-title":"Int J Mol Sci"},{"key":"1420_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1124\/dmd.32.4.413","volume":"32","author":"V Uchaipichat","year":"2004","unstructured":"Uchaipichat V, Mackenzie PI, Guo X-H, et al. Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos. 2004;32:413\u201323.","journal-title":"Drug Metab Dispos"},{"key":"1420_CR16","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.3390\/pharmaceutics13111961","volume":"13","author":"A Czyrski","year":"2021","unstructured":"Czyrski A, Resztak M, Swiderski P, Brylak J, Glowka FK. The overview on the pharmacokinetic and pharmacodynamic interactions of triazoles. Pharmaceutics. 2021;13:1961.","journal-title":"Pharmaceutics"},{"key":"1420_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00228-006-0159-2","volume":"62","author":"E Krupka","year":"2006","unstructured":"Krupka E, Venisse N, Lafay C, et al. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers. Eur J Clin Pharmacol. 2006;62:653\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"1420_CR18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/jcph.637","volume":"56","author":"RC Ayala","year":"2016","unstructured":"Ayala RC, Arya V, Younis IR. Design features of drug\u2013drug interaction trials between antivirals and oral contraceptives. J Clin Pharmacol. 2016;56:541\u20137.","journal-title":"J Clin Pharmacol"},{"key":"1420_CR19","unstructured":"Bioanalytical method validation. Guidance for Industry. United States Food and Drug Administration; 2018. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry. Accessed 28 Aug 2023."},{"key":"1420_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006761","volume":"96","author":"PJ Patel","year":"2017","unstructured":"Patel PJ, Hayward KL, Rudra R, et al. Multimorbidity and polypharmacy in diabetic patients with NAFLD: implications for disease severity and management. Medicine (Baltimore). 2017;96: e6761.","journal-title":"Medicine (Baltimore)"},{"key":"1420_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1124\/dmd.120.000273","volume":"49","author":"HM Weiss","year":"2021","unstructured":"Weiss HM, Langenickel T, Cain M, et al. Clinical investigation of metabolic and renal clearance pathways contributing to the elimination of fevipiprant using probenecid as perpetrator. Drug Metab Dispos. 2021;49:389\u201394.","journal-title":"Drug Metab Dispos"},{"key":"1420_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5414\/CP202158","volume":"53","author":"D Devineni","year":"2015","unstructured":"Devineni D, Vaccaro N, Murphy J, et al. Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015;53:115\u201328.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1420_CR23","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/cpt.2105","volume":"109","author":"BJ Kirby","year":"2021","unstructured":"Kirby BJ, Lutz JD, Yue MS, et al. Organic anion transporting polypeptide inhibition dramatically increases plasma exposure but not pharmacodynamic effect nor inferred hepatic intracellular exposure of firsocostat. Clin Pharmacol Ther. 2021;109:1334\u201341.","journal-title":"Clin Pharmacol Ther"},{"key":"1420_CR24","unstructured":"Drugs. United States Food and Drug Administration. Available at: https:\/\/www.fda.gov\/drugs. Accessed 20 Sep 2023."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01420-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01420-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01420-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T14:17:43Z","timestamp":1730297863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01420-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1420"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01420-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]},"assertion":[{"value":"25 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Gilead Sciences, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Elijah J. Weber, Islam R. Younis, Cara Nelson, and Ahmed A. Othman were employees of Gilead Sciences, Inc. at the time of this work and may own stock in Gilead Sciences, Inc. Ann R. Qin and Timothy R. Watkins are employees of, and may own stock in, Gilead Sciences, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was reviewed and approved by an IRB (Salus IRB; 2111 West Braker Lane, Suite 400, Austin, TX 78758, USA).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent before study participation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors approved this manuscript for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Gilead Sciences shares anonymized individual patient data upon request, or as required by law or regulation, with qualified external researchers based on submitted curriculum vitae and reflecting non-conflicts of interest. The request proposal must also include a statistician. Approval of such requests is at Gilead Science's discretion and is dependent on the nature of the request, the merit of the research proposed, the availability of the data, and the intended use of the data. Data requests should be sent to datarequest@gilead.com.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data"}},{"value":"CN and ARQ designed the study. EJW, IRY, CN, ARQ, TRW, and AAO analyzed and interpreted the data and drafted the manuscript. All authors revised and approved the final version of the manuscript submitted for publication.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}